ReviewMolecular medicine reports2018
The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review).
Review in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Efficacy and safety of ivonescimab in non-small cell lung cancer: a systematic review and meta-analysis of emerging clinical data.Frontiers in pharmacology · 2026Pooled it
- Intracavitary perfusion with bevacizumab plus cisplatin versus cisplatin alone for malignant pleural effusion in lung cancer patients: a meta-analysis of randomized controlled trials.World journal of surgical oncology · 2025Pooled it
- Pooled it
- A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.Thoracic cancer · 2020Trial
- OsimertinibTranslational lung cancer research · 2026Article
- Unraveling the multidimensional pleural ecosystem of lung cancer-associated malignant pleural effusion.Cancer cell international · 2026Review
- Advances in semaphorin 3B research in tumors (Review).Molecular and clinical oncology · 2026Review
- CT prediction of malignancy in part-solid pulmonary nodules based on vascular interruption and distortion.Frontiers in medicine · 2026Article
- Application of pleural effusion cell blocks for immunohistochemistry and EGFR gene mutation testing for advanced lung cancer.Experimental and therapeutic medicine · 2026Article
- Diagnostic value of CEACAM6 and HE4 in pleural fluid for malignant pleural effusion.Annals of medicine · 2025Article
- Intrapleural Steroid Therapy for Recurrent Malignant Pleural Effusion: A Case Report.Clinical case reports · 2025Article
- Effect of NADPH oxidase inhibitor apocynin on human lung cancer A549 cells via Bcl-2, Bax, caspase-3, and NF-κB signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Medical thoracoscopic photodynamic therapy for metastatic pleural tumors with malignant effusion: an exploratory pilot study.Frontiers in oncology · 2025Article
- Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion.Translational lung cancer research · 2024Article
- In Vitro and In Silico Studies on 4-Nitroacetophenone Thiosemicarbazone Potential Cytotoxicity Against A549 Cell Lines.Applied biochemistry and biotechnology · 2024Article
- Review
- Article
- Different types of tumor microvessels in stage I-IIIA squamous cell lung cancer and their clinical significance.World journal of clinical oncology · 2024Article
- Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer.Clinical and translational medicine · 2024Article
- Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications.Cancer cell international · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural effusion (MPE) is a severe medical condition, which can result in breathlessness, pain, cachexia and reduced physical activity. It can occur in almost all types of malignant tumors; however, lung cancer is the most common cause of MPE, accounting for ~1/3 of clinical cases. Although there are numerous therapeutic approaches currently available for the treatment of MPE, none are fully effective and the majority can only alleviate the symptoms of the patients. Vascular endothelial growth factor (VEGF) has now been recognized as one of the most important regulatory factors in tumor angiogenesis, which participates in the entire process of tumor growth through its function to stimulate tumor angiogenesis, activate host vascular endothelial cells and promote malignant proliferation. Novel drugs targeting VEGF, including endostar and bevacizumab, have been developed and approved for the treatment of various tumors. Data from recent clinical studies have demonstrated that drugs targeting VEGF are effective and safe for the clinical management of MPE. Therefore, VEGF‑targeting represents a promising novel strategy for the diagnosis and treatment of MPE. The present review summarized recent advances in the role of VEGF in the pathogenesis, diagnosis and clinical management of MPE in patients with non‑small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.